Long-Term Prophylaxis for Hereditary C1 Inhibitor Deficiency With Recurrent Angioedema Attacks Affecting Quality of Life

In patients with hereditary C1 inhibitor deficiency, recurrent angioedema attacks that are frequent and severe enough to impair daily functioning and quality of life represent a clinical threshold that guides the decision to initiate structured long-term prophylactic treatment. This decision is individualized — there are no rigid universal criteria — and is shaped by each patient's specific attack burden and overall circumstances.

Clinical scenario Recurrent angioedema attacks whose frequency and severity meaningfully impact the patient's quality of life. Clinicians weigh attack frequency, attack severity, comorbid conditions, patient preferences, and access to emergent treatment when deciding whether and when to initiate long-term prophylaxis.

Treatment approach (partial overview) First-line long-term prophylaxis draws on plasma-derived C1 inhibitor replacement — available in both intravenous and subcutaneous formulations — as well as a monoclonal inhibitor of plasma kallikrein. The specific agents, escalation criteria, and dosing strategy are detailed in the full structured protocol.

Complete regimen, dosing guidance, and escalation algorithm available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jaip.2020.08.046

The decision on when to use long-term prophylactic treatment cannot be made on rigid criteria but should reflect the needs of the individual patient.
Decisions regarding which patients should be considered for LTP should take into account the patient's QoL and treatment preferences in the context of attack frequency, attack severity, comorbid conditions, and access to emergent treatment.
Long-term prophylactic treatment of HAE-C1INH should include first-line medications (IV C1INH, SC C1INH, or lanadelumab).
The first-line therapies include IV pdC1INH replacement (Cinryze), subcutaneous (SC) pdC1INH replacement (Haegarda), and a monoclonal inhibitor of plasma kallikrein (lanadelumab, Takhzyro).

View source ↗